IONS 241220 40.00C (IONS241220C40000) Stock Options, News & Quotes

0.20
-0.15-42.86%

15min DelayTrading Dec 3 10:18 ET

0.30High0.20Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Apr 7 23:52

$Ionis Pharmaceuticals (IONS.US)$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”

Moomoo AI

Mar 17 10:16

Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.

Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

Moomoo AI

Feb 29 08:12

Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.

Press Release: Ionis Announces New Chief Global Product Strategy Officer to Lead Next Phase of Commercial Growth

Moomoo AI

Feb 19 13:10

Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.

Insider Sellers Might Regret Selling Ionis Pharmaceuticals Shares at a Lower Price Than Current Market Value

Moomoo AI

Dec 29, 2023 02:22

Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now